Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review

Detalhes bibliográficos
Autor(a) principal: Batel-Marques, Francisco
Data de Publicação: 2019
Outros Autores: Pereira, Diogo, Mendes, Diogo, Alves, Carlos, Penedones, Ana
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/106839
https://doi.org/10.1136/bmjopen-2019-032522
Resumo: Data supporting the use of oral antidiabetic drugs mainly rely on data from premarketing clinical trials. Real-world data studies are crucial to evaluate effectiveness of drugs. The aim of this systematic review is to compare the results obtained for efficacy and effectiveness endpoints on clinical trials and those obtained from routine clinical practice of dipeptidyl peptidase-4 inhibitors. Methods and analysis This systematic review will include randomised controlled trials and observational studies evaluating the efficacy and effectiveness of dipeptidyl peptidase-4 inhibitors, respectively. A literature search will be performed at Medline, Embase, Cochrane Controlled Register of Trials and ClinicalTrials. gov. Search terms comprised the drug name (including the pharmacotherapeutic class and the international non-proprietary name). Data on haemoglobin A1C, blood glucose and body weight will be retrieved. The risk of bias will be independently assessed according to the checklist proposed by Downs and Black. Data will be analysed using descriptive statistics and meta-analysis when applicable. Ethics and dissemination Ethical approval is not required as no primary data are collected. This systematic review will be disseminated through a peer-reviewed publication and at conference meetings.
id RCAP_40408ba74ca8ae9020acaccc288cdef5
oai_identifier_str oai:estudogeral.uc.pt:10316/106839
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic reviewDIABETES & ENDOCRINOLOGYProtocols & guidelinessystematic reviewBlood GlucoseBody WeightClinical Trials as TopicDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsGlycated HemoglobinHumansHypoglycemic AgentsMeta-Analysis as TopicResearch DesignSystematic Reviews as TopicTreatment OutcomeData supporting the use of oral antidiabetic drugs mainly rely on data from premarketing clinical trials. Real-world data studies are crucial to evaluate effectiveness of drugs. The aim of this systematic review is to compare the results obtained for efficacy and effectiveness endpoints on clinical trials and those obtained from routine clinical practice of dipeptidyl peptidase-4 inhibitors. Methods and analysis This systematic review will include randomised controlled trials and observational studies evaluating the efficacy and effectiveness of dipeptidyl peptidase-4 inhibitors, respectively. A literature search will be performed at Medline, Embase, Cochrane Controlled Register of Trials and ClinicalTrials. gov. Search terms comprised the drug name (including the pharmacotherapeutic class and the international non-proprietary name). Data on haemoglobin A1C, blood glucose and body weight will be retrieved. The risk of bias will be independently assessed according to the checklist proposed by Downs and Black. Data will be analysed using descriptive statistics and meta-analysis when applicable. Ethics and dissemination Ethical approval is not required as no primary data are collected. This systematic review will be disseminated through a peer-reviewed publication and at conference meetings.BMJ Publishing Group2019-09-17info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/106839http://hdl.handle.net/10316/106839https://doi.org/10.1136/bmjopen-2019-032522eng2044-60552044-6055Batel-Marques, FranciscoPereira, DiogoMendes, DiogoAlves, CarlosPenedones, Anainfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-04-26T10:35:37Zoai:estudogeral.uc.pt:10316/106839Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:23:14.264288Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
title Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
spellingShingle Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
Batel-Marques, Francisco
DIABETES & ENDOCRINOLOGY
Protocols & guidelines
systematic review
Blood Glucose
Body Weight
Clinical Trials as Topic
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors
Glycated Hemoglobin
Humans
Hypoglycemic Agents
Meta-Analysis as Topic
Research Design
Systematic Reviews as Topic
Treatment Outcome
title_short Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
title_full Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
title_fullStr Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
title_full_unstemmed Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
title_sort Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
author Batel-Marques, Francisco
author_facet Batel-Marques, Francisco
Pereira, Diogo
Mendes, Diogo
Alves, Carlos
Penedones, Ana
author_role author
author2 Pereira, Diogo
Mendes, Diogo
Alves, Carlos
Penedones, Ana
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Batel-Marques, Francisco
Pereira, Diogo
Mendes, Diogo
Alves, Carlos
Penedones, Ana
dc.subject.por.fl_str_mv DIABETES & ENDOCRINOLOGY
Protocols & guidelines
systematic review
Blood Glucose
Body Weight
Clinical Trials as Topic
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors
Glycated Hemoglobin
Humans
Hypoglycemic Agents
Meta-Analysis as Topic
Research Design
Systematic Reviews as Topic
Treatment Outcome
topic DIABETES & ENDOCRINOLOGY
Protocols & guidelines
systematic review
Blood Glucose
Body Weight
Clinical Trials as Topic
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors
Glycated Hemoglobin
Humans
Hypoglycemic Agents
Meta-Analysis as Topic
Research Design
Systematic Reviews as Topic
Treatment Outcome
description Data supporting the use of oral antidiabetic drugs mainly rely on data from premarketing clinical trials. Real-world data studies are crucial to evaluate effectiveness of drugs. The aim of this systematic review is to compare the results obtained for efficacy and effectiveness endpoints on clinical trials and those obtained from routine clinical practice of dipeptidyl peptidase-4 inhibitors. Methods and analysis This systematic review will include randomised controlled trials and observational studies evaluating the efficacy and effectiveness of dipeptidyl peptidase-4 inhibitors, respectively. A literature search will be performed at Medline, Embase, Cochrane Controlled Register of Trials and ClinicalTrials. gov. Search terms comprised the drug name (including the pharmacotherapeutic class and the international non-proprietary name). Data on haemoglobin A1C, blood glucose and body weight will be retrieved. The risk of bias will be independently assessed according to the checklist proposed by Downs and Black. Data will be analysed using descriptive statistics and meta-analysis when applicable. Ethics and dissemination Ethical approval is not required as no primary data are collected. This systematic review will be disseminated through a peer-reviewed publication and at conference meetings.
publishDate 2019
dc.date.none.fl_str_mv 2019-09-17
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/106839
http://hdl.handle.net/10316/106839
https://doi.org/10.1136/bmjopen-2019-032522
url http://hdl.handle.net/10316/106839
https://doi.org/10.1136/bmjopen-2019-032522
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2044-6055
2044-6055
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv BMJ Publishing Group
publisher.none.fl_str_mv BMJ Publishing Group
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134120141389824